Aisling Capital Overview

  • Investor Type
  • Venture Capital

  • Status
  • Active

  • Professionals
  • 9

Professionals

  • Investments
  • 237

  • Portfolio
  • 19

  • Exits
  • 155

Exits

Aisling Capital General Information

Company Description

Founded in 2000, Aisling Capital is a venture capital firm based in New York, New York. The firm seeks to invest in healthcare & life science sectors based in the Canada Europe & American regions.

Business Details

Formerly Known As
Perseus Soros Management
Year Founded
2000
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Other Investor Types
PE/Buyout
Corporate Office
  • 489 Fifth Avenue
  • Floor 10
  • New York, NY 10017
  • United States
+1 (212) 000-0000

Aisling Capital Investments & Acquisitions (237)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
BridgeBio Oncology Therapeutics 02-May-2024 Later Stage VC 00000 Drug Discovery Clinical Trials - Phase 1
Mindful Health Solutions 01-Jan-2024 00 000000000 Clinics/Outpatient Services Generating Revenue
Bicara Therapeutics 06-Dec-2023 00000 00000 00000 Drug Discovery Clinical Trials - Phase 2
COMPASS Pathways 18-Aug-2023 0000 00000 Clinics/Outpatient Services Clinical Trials - Phase 2
Garuda Therapeutics 24-Jan-2023 00000 00000 000.00 Drug Discovery Generating Revenue 0000 000000 00
Wugen 16-Dec-2022 00000 00000 00000 Drug Discovery Clinical Trials - Phase 2 000000 0000000
Treeline Biosciences 11-Oct-2022 00000 00000 00000 Drug Discovery Startup 000000 0000
Forge Biologics 12-Sep-2022 00000 00000 0000 Drug Discovery Generating Revenue 000000 000000 00
Dren Bio 14-Jun-2022 Early Stage VC 000.00 Biotechnology Pre-Clinical Trials 000000 000000 00
Antios Therapeutics 03-Nov-2021 Early Stage VC 0000 Drug Discovery Out of Business
You’re viewing 10 of 237 investments and acquisitions. Get the full list »

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aisling Capital Exits (155)

Company Name Exit Date Exit Type Exit Size
Monte Rosa Therapeutics 16-May-2024 Public Investment 2nd Offering 0000
Forge Biologics 21-Dec-2023 000000000000000000 00000
Seachaid Pharmaceuticals 01-Dec-2023 000 00 00000000
Zosano Pharma 26-Aug-2022 000000000000000000 000
Medical Knowledge Group 01-Feb-2022 0000000000 00.000
Syndax 17-Dec-2021 000000 0000000000 000.00
Elevation Oncology 25-Jun-2021 000 00000
Monte Rosa Therapeutics 24-Jun-2021 000 00000
Talaris Therapeutics 07-May-2021 IPO 00000
AEON Biopharma 16-Apr-2021 Secondary Transaction - Private
You’re viewing 10 of 155 exits. Get the full list »

Aisling Capital Fund Performance

Fund Name Vintage Size Dry Powder DPI RVPI TVPI IRR

This information is available in the PitchBook Platform. To explore Aisling Capital‘s full profile, request access.

Request a free trial

Aisling Capital Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Aisling Capital Management, Team & Partners (34)

Name Title Deals Funds Boards Office
Robert Wenzel Chief Financial Officer & Chief Compliance Officer, Legal New York, NY
Andrew Schiff MD Managing Partner 00 0 0 New York, NY
Steven Elms Managing Partner 00 0 0 New York, NY
Eric Aguiar MD Partner 00 0 0 New York, NY
Sunny Reddy Principal New York, NY
You’re viewing 5 of 34 team members. Get the full list »

Aisling Capital Co-Investors (123)

Name With Exits Lead Partner Series Industry
Cormorant Asset Management 5 0 0 Series chart Industry bar
Fidelity Management & Research 0 0 Series chart Industry bar
Omega Funds 0 0 Series chart Industry bar
Rock Springs Capital 0 0 Series chart Industry bar
Citadel Enterprise Americas 0 0 Series chart Industry bar
You’re viewing 5 of 123 co-investors. Get the full list »

Aisling Capital FAQs

  • What is Aisling Capital?

    Founded in 2000, Aisling Capital is a venture capital firm based in New York, New York.

  • When was Aisling Capital founded?

    Aisling Capital was founded in 2000.

  • Who is the founder of Aisling Capital?

    Dennis Purcell is the founder of Aisling Capital.

  • Where is Aisling Capital headquartered?

    Aisling Capital is headquartered in New York, NY.

  • What is Aisling Capital's total asset value?

    Aisling Capital has around 00000 in total assets under management.

  • How many investments has Aisling Capital made?

    Aisling Capital has made 237 investments.

  • What has Aisling Capital invested in?

    Aisling Capital has made numerous investments in companies like BridgeBio Oncology Therapeutics, Mindful Health Solutions, and Bicara Therapeutics within the Drug Discovery and Clinics/Outpatient Services industries.

  • What has Aisling Capital invested in recently?

    Aisling Capital's latest investment was on 02-May-2024 in BridgeBio Oncology Therapeutics, a company within the Drug Discovery industry.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »